Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorOlcucuoglu, Erkan
dc.contributor.authorSirin, Mehmet Emin
dc.contributor.authorAydog, Gulden
dc.contributor.authorGazel, Eymen
dc.contributor.authorTastemur, Sedat
dc.contributor.authorOdabas, Oner
dc.date.accessioned2019-11-24T21:01:45Z
dc.date.available2019-11-24T21:01:45Z
dc.date.issued2017
dc.identifier.issn2080-4806
dc.identifier.issn2080-4873
dc.identifier.urihttps://dx.doi.org/10.5173/ceju.2017.1357
dc.identifier.urihttps://hdl.handle.net/20.500.12513/3559
dc.descriptionWOS: 000418412900003en_US
dc.descriptionPubMed ID: 29410884en_US
dc.description.abstractIntroduction It has been shown that CD47 is an important diagnostic and prognostic marker in many cancer types. However, the relationship between CD47 and bladder tumor stage has not been shown in previous studies. To the best of our knowledge, this is the first study investigating the association of CD47 with stages of bladder cancer. Material and methods Surgical specimens of 175 patients were included in the study. The CD47 staining assessment was performed in the following categories; none, focal, moderate and diffuse. The statistics of the study were tested using t-test and analysis of variance. Results We demonstrated much less CD47 staining extent in Ta tumor pathology compared to T1 and T1+T2+T3+T4 tumor pathology (p = 0.034 and p = 0.016, respectively). We also showed that the average value of CD47 staining extent with CIS+ was significantly higher compared to CIS-among NMIBC p = 0.0248). However, no significant differences in CD47 staining pattern were observed in the following study groups: high vs. low-grade tumors in non-muscle invasive bladder cancer (NMIBC); MIBC (T2-T4) vs. NMIBC; lymph node involvement (N1-N3) vs. non- lymph node involvement (N0) in MIBC (T2-T4). Conclusions Our study demonstrated that CD47 might have a critical role in the progression of Ta to T1 stage. Furthermore, we showed that CD47 is highly expressed in CIS+ NMIBC compared to CIS-NMIBC. Thus, differentiating stages with the help of this new potential marker may help clinicians treat bladder tumors better. Future studies to determine the role of CD47 on pathophysiology, diagnosis and prognosis of bladder tumor are warranted.en_US
dc.language.isoengen_US
dc.publisherPOLISH UROLOGICAL ASSOCen_US
dc.relation.isversionof10.5173/ceju.2017.1357en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCD47en_US
dc.subjectbladder tumoren_US
dc.subjectimmunohistochemical stainen_US
dc.titleRelationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumoren_US
dc.typearticleen_US
dc.relation.journalCENTRAL EUROPEAN JOURNAL OF UROLOGYen_US
dc.contributor.departmentKırşehir Ahi Evran Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri, Üroloji ABDen_US
dc.identifier.volume70en_US
dc.identifier.issue4en_US
dc.identifier.startpage349en_US
dc.identifier.endpage355en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster